Prévalence des infections associées aux soins en oncohématologie en Tunisie
Mots-clés :
Infection associée aux soins, prévalence ponctuelle, oncohématologie.Résumé
Abstract
Background : Healthcare-associated infections (HAIs) are with high rates of mortality and an additional cost, in onco-hematology patients.
Aim : The study aims to assess the prevalence trends of HAIs in the onco-hematology ward of the Tunisian National Bone Marrow Transplant Center (NBMTC), and to determine the principal associated risk factors.
Methods: Six repeated point prevalence surveys were conducted, from May 2018 to March 2019, using a two months interval. All patients hospitalized in the day of the survey were included. Risk factors of HAIs were expressed as odds ratios (ORs) with 95% confidence intervals (CIs). They were assessed using a logistic regression model.
Results: Nineteen patients out of a total of 74 patients have been diagnosed with 19 HAIs, representing a prevalence of 25.7%. No significant downward or upward trend of prevalence was revealed over time (p=0.3). The most common HAI was respiratory tract infection (57.9%) with a prevalence of 14.9%. Multiple logistic regression analysis revealed that HAI was significantly associated with neutropenia (Adjusted OR: 14; 95% CI: 1.5-127; p=0.01) and duration of central venous catheter (Adjusted OR: 1.1; 95% CI: 1-1.2; p=0.005).
Conclusion: High prevalence of HAIs in our center with a high rate of mortality, requiring identifying potential problems in infection control practices.
Téléchargements
Références
1. Dettenkofer M, Wenzlerâ€Rottele S, Babikir R, et al. Surveillance of nosocomial sepsis and pneumonia in patients with a bone marrow or peripheral blood Stem cell transplant: A multicenter project. Clin Infect Dis 2005 ; 40(7) :926‑31. DOI : 10.1086/428046. 2. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. AJIC 2008 ; 36(5) :309‑32. DOI : 10.1016/j.ajic.2008.03.002. 3. Société française d'anesthésie et de réanimation (SFAR), Société de réanimation de langue française (SRLF). Prévention des infections nosocomiales en réanimation (transmission croisée et nouveau-né exclus). Ann Fr Anesth Réanim [Internet] 2009 october 13 [cited 2020 May 5] ; 28(10). Available from : https://www.em-consulte.com/en/article/232290. 4. Simon A, Ammann RA, Bode U, et al. Healthcare-associated infections in pediatric cancer patients: results of a prospective surveillance study from university hospitals in Germany and Switzerland. BMC Infect Dis 2008 ; 8(1) :70. DOI : 10.1186/1471-2334-8-70. 5. Al-Tonbary YA, Soliman OE, Sarhan MM, et al. Nosocomial infections and fever of unknown origin in pediatric hematology/oncology unit: a retrospective annual study. World J Pediatr 2011 ; 7(1) :60‑4. DOI : 10.1007/s12519-010-0212-1. 6. The Korean Network for Study of Infectious Diseases (KONSID), Kang C-I, Chung DR, Ko KS, Peck KR, Song J-H. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann Hematol 2012 ; 91(1) :115‑21. DOI : 10.1007/s00277-011-1247-7. 7. Société Française de Microbiologie. Remic : Referentiel en microbiologie medicale. 6ème édition. Paris: Société Française de Microbiologie; 2018. 8. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin Microbiol Infect 2008 ; 14(10) :982‑4. DOI : 10.1111/j.1469-0691.2008.02086.x. 9. Huoi C, Vanhems P, Nicolle M-C, Michallet M, Bénet T. Incidence of hospital-acquired pneumonia, bacteraemia and urinary tract infections in patients with haematological malignancies, 2004-2010 : A surveillance-based study. Plos One [Internet] 2013 march 28 [Cited 2020 May 13] ; 8(3). Available from : https://dx.plos.org/10.1371/journal.pone.0058121 10. Ciofi degli Atti ML, Cuttini M, Ravà L, et al. Trend of healthcare-associated infections in children: Annual prevalence surveys in a research hospital in Italy, 2007-2010. J Hosp Infect 2012 ; 80(1) :6‑12. DOI : 10.1016/j.jhin.2011.11.004. 11. Balletto E, Mikulska M. BACTERIAL INFECTIONS IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS. Mediterr J Hematol Infect Dis [Internet] 2015 july 16 [Cited 2020 May 12] ; 7(1). Available from : http://www.mjhid.org/index.php/mjhid/article/view/2015.045. 12. Yemişen M, Balkan Ä°Ä°, SalihoÄŸlu A, et al. The changing epidemiology of bloodstream infections and resistance in hematopoietic Stem Cell Transplantation Recipients. JTH 2016 ; 33(3) :216‑22. DOI : 10.4274/tjh.2014.0378. 13. Freeman J, McGowan JE. Risk factors for nosocomial infection. J Infect Dis 1978 ; 138(6) :811‑9. DOI : 10.1093/infdis/138.6.811. 14. Godbole G, Gant V. Respiratory tract infections in the immunocompromised. J Infect Dis 2013 ; 19(3) :7. DOI: 10.1002/jmv.25432. 15. Küpeli E, EyüboÄŸlu FÖ, Haberal M. Pulmonary infections in transplant recipients : Current Opinion in Pulmonary Medicine. Curr Opin Pulm Med 2012 ; 18(3) :202‑12. DOI : 10.1097/MCP.0b013e328352104f. 16. Kafazi A, Stylianou C, Zwmas A, et al. Surveillance of healthcare-associated infections rates in hematology-oncology patients. J Integr Oncol 2017 ; 06 (04). 200-7. DOI : 10.4172/2329-6771.1000200. 17. Buchheidt D, Böhme A, Cornely OA, et al. Diagnosis and treatment of documented infections in neutropenic patients: Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003 ; 82(S2) :S127‑32. DOI : 10.1007/s00277-003-0766-2. 18. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003 ; 115(7) :529‑35. DOI : 10.1016/j.amjmed.2003.07.005. 19. Urrea M, Rives S, Cruz O, Navarro A, José GarcıÌa J, Estella J. Nosocomial infections among pediatric hematology/oncology patients : Results of a prospective incidence study. AJIC 2004 ; 32(4) :205‑8. DOI : 10.1016/j.ajic.2003.10.013. 20. Rodloff AC, Goldstein EJC, Torres A. Two decades of imipenem therapy. J Antimicrob Chemother 2006 ; 58(5) :916‑29. DOI : 10.1093/jac/dkl354.
